{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T22:06:50Z","timestamp":1771279610306,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00520-026-10345-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:34:20Z","timestamp":1770014060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial"],"prefix":"10.1007","volume":"34","author":[{"given":"Edis","family":"Gasanin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Bezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulla","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedeborg","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"10345_CR1","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2013state of the art. Support Care Cancer 19:S43\u2013S47. https:\/\/doi.org\/10.1007\/s00520-010-1003-x","journal-title":"Support Care Cancer"},{"key":"10345_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP (2021) Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun 26:100278. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"10345_CR3","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"10345_CR4","doi-asserted-by":"publisher","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL, Aapro M, Dennis K, Hesketh PJ, Navari RM, Schwartzberg L, Affronti ML, Garcia-Del-Barrio MA, Chan A, Celio L, Chow R, Fleury, Gralla RJ, Giusti R, Jahn F, Iihara H, Maranzano E, Radhakrishnan V, Saito M, Sayegh P, Bosnjak S, Zhang L, Lee J, Ostwal V, Smit T, Zilic A, Jordan K, Scott\u00e9 F; participants of the MASCC\/ESMO Consensus Conference 2022 (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9:102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","DOI":"10.1016\/j.esmoop.2023.102195"},{"key":"10345_CR5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Antiemesis. Version 2.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 26 August 2025"},{"key":"10345_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"10345_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03380-0","volume":"20","author":"F Rajati","year":"2022","unstructured":"Rajati F, Ahmadi N, Naghibzadeh ZAS, Kazeminia M (2022) The global prevalence of oropharyngeal dysphagia in different populations: a systematic review and meta-analysis. J Transl Med 20:175. https:\/\/doi.org\/10.1186\/s12967-022-03380-0","journal-title":"J Transl Med"},{"key":"10345_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cger.2013.10.009","volume":"30","author":"A Khan","year":"2014","unstructured":"Khan A, Carmona R, Traube M (2014) Dysphagia in the elderly. Clin Geriatr Med 30:43\u201353. https:\/\/doi.org\/10.1016\/j.cger.2013.10.009","journal-title":"Clin Geriatr Med"},{"key":"10345_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s00455-014-9584-z","volume":"30","author":"B Kertscher","year":"2015","unstructured":"Kertscher B, Speyer R, Fong E, Georgiou AM, Smith M (2015) Prevalence of oropharyngeal dysphagia in the Netherlands: a telephone survey. Dysphagia 30:114\u2013120. https:\/\/doi.org\/10.1007\/s00455-014-9584-z","journal-title":"Dysphagia"},{"key":"10345_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00455-016-9695-9","volume":"31","author":"C Takizawa","year":"2016","unstructured":"Takizawa C, Gemmell E, Kenworthy J, Speyer R (2016) A systematic review of the prevalence of oropharyngeal dysphagia in stroke, Parkinson\u2019s disease, Alzheimer\u2019s disease, head injury, and pneumonia. Dysphagia 31:434\u2013441. https:\/\/doi.org\/10.1007\/s00455-016-9695-9","journal-title":"Dysphagia"},{"key":"10345_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/geriatrics5030045","volume":"5","author":"TF Lin","year":"2020","unstructured":"Lin TF, Shune S (2020) Chronic obstructive pulmonary disease and dysphagia: a synergistic review. Geriatrics (Basel) 5:45. https:\/\/doi.org\/10.3390\/geriatrics5030045","journal-title":"Geriatrics (Basel)"},{"key":"10345_CR12","doi-asserted-by":"publisher","unstructured":"Gatta G, Botta L, S\u00e1nchez MJ, Anderson LA, Pierannunzio D, Licitra L; EUROCARE Working Group (2015) Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 population-based study. Eur J Cancer 51: 2130-2143. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.043","DOI":"10.1016\/j.ejca.2015.07.043"},{"key":"10345_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"10345_CR14","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.4317\/jced.51313","volume":"6","author":"C Alvari\u00f1o-Mart\u00edn","year":"2014","unstructured":"Alvari\u00f1o-Mart\u00edn C, Sarri\u00f3n-P\u00e9rez MG (2014) Prevention and treatment of oral mucositis in patients receiving chemotherapy. J Clin Exp Dent 6:e74\u2013e80. https:\/\/doi.org\/10.4317\/jced.51313","journal-title":"J Clin Exp Dent"},{"key":"10345_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08151-1","volume":"31","author":"MB Agholme","year":"2023","unstructured":"Agholme MB, Dahll\u00f6f G, T\u00f6rl\u00e9n JK, Majorana A, Brennan MT, von B\u00fcltzingsl\u00f6wen I, Tan PL, Hu S, Sim YF, Hong C (2023) Incidence, severity, and temporal development of oral complications in pediatric allogeneic hematopoietic stem cell transplant patients \u2013 a multicenter study. Support Care Cancer 31:702. https:\/\/doi.org\/10.1007\/s00520-023-08151-1","journal-title":"Support Care Cancer"},{"key":"10345_CR16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26888","volume":"14","author":"G Tsalimas","year":"2022","unstructured":"Tsalimas G, Evangelopoulos DS, Benetos IS, Pneumaticos S (2022) Dysphagia as a postoperative complication of anterior cervical discectomy and fusion. Cureus 14:e26888. https:\/\/doi.org\/10.7759\/cureus.26888","journal-title":"Cureus"},{"key":"10345_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.anorl.2013.09.006","volume":"132","author":"S Servagi-Vernat","year":"2015","unstructured":"Servagi-Vernat S, Ali D, Roubieu C, Durdux C, Laccourreye O, Giraud P (2015) Dysphagia after radiotherapy: state of the art and prevention. Eur Ann Otorhinolaryngol Head Neck Dis 132:25\u201329. https:\/\/doi.org\/10.1016\/j.anorl.2013.09.006","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10345_CR18","first-page":"97","volume":"103","author":"JM Wilkinson","year":"2021","unstructured":"Wilkinson JM, Codipilly DC, Wilfahrt RP (2021) Dysphagia: evaluation and collaborative management. Am Fam Physician 103:97\u2013106","journal-title":"Am Fam Physician"},{"key":"10345_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DDDT.S76158","volume":"9","author":"RM Navari","year":"2014","unstructured":"Navari RM (2014) Profile of netupitant\/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155\u2013161. https:\/\/doi.org\/10.2147\/DDDT.S76158","journal-title":"Drug Des Devel Ther"},{"key":"10345_CR20","unstructured":"U.S. Food and Drug Administration (2014) Drug Approval Package. Akynzeo (netupitant and palonosetron capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205718Orig1s000TOC.cfm. Accessed 26 August 2025"},{"key":"10345_CR21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","volume":"29","author":"L Schwartzberg","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M (2018) Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol 29:1535\u20131540. https:\/\/doi.org\/10.1093\/annonc\/mdy169","journal-title":"Ann Oncol"},{"key":"10345_CR22","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","volume":"25","author":"L Schwartzberg","year":"2020","unstructured":"Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E (2020) Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist 25:e589\u2013e597. https:\/\/doi.org\/10.1634\/theoncologist.2019-0527","journal-title":"Oncologist"},{"issue":"4","key":"10345_CR23","doi-asserted-by":"publisher","first-page":"e1127","DOI":"10.1002\/cnr2.1127","volume":"1","author":"M Aapro","year":"2018","unstructured":"Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V (2018) Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken) 1(4):e1127. https:\/\/doi.org\/10.1002\/cnr2.1127","journal-title":"Cancer Rep (Hoboken)"},{"key":"10345_CR24","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1182\/blood.V130.Suppl_1.2180.2180","volume":"130","author":"M Karthaus","year":"2017","unstructured":"Karthaus M, Klare P, Heilmann V, Klausmann G, Schilling J (2017) Quality of life and patient reported outcome (PRO) in patients receiving high and moderate emetogenic chemotherapy (Ctx) - results of a German non-interventional study with NEPA - a netupitant\/palonosetron fixed dose combination. Blood 130:2180. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.2180.2180","journal-title":"Blood"},{"key":"10345_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40520-025-02950-8","volume":"37","author":"F Dini","year":"2025","unstructured":"Dini F, Mancini S, Girelly A, Ercolini DP, Reggiani A, Alonso YS, Inzitari M, Bellelli G, Marengoni A, Gentile S, Morandi A (2025) Dysphagia and geriatric syndromes in older patients admitted to an intermediate care unit: prospective observational study. Aging Clin Exp Res 37:89. https:\/\/doi.org\/10.1007\/s40520-025-02950-8","journal-title":"Aging Clin Exp Res"},{"key":"10345_CR26","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the investigation of bioequivalence https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 26 August 2025"},{"key":"10345_CR27","unstructured":"European Medicines Agency (2015) Questions & answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-and-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf. Accessed 26 August 2025"},{"key":"10345_CR28","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration (2001) Guidance for industry: statistical approaches to establishing bioequivalence. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-approaches-establishing-bioequivalence. Accessed 26 August 2025"},{"key":"10345_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12877-019-1337-2","volume":"19","author":"E Belissa","year":"2019","unstructured":"Belissa E, Vallet T, Laribe-Caget S, Chevallier A, Chedhomme FX, Abdallah F, Bachalat N, Belbachir SA, Imad Boulaich I, Bloch V, Delahaye A, Depoisson M, Wojcicki AD, Gibaud S, Grancher AS, Guinot C, Lachuer C, Lechowski L, Leglise P, Mahiou A, Meaume S, Michel C, Michelon H, Orven Y, Perquy I, Piccoli M, Rabus M, Ribemont AC, Rwabihama JP, Trouvin JH, Ruiz F, Boudyet V (2019) Acceptability of oral liquid pharmaceutical products in older adults: palatability and swallowability issues. BMC Geriatr 19:344. https:\/\/doi.org\/10.1186\/s12877-019-1337-2","journal-title":"BMC Geriatr"},{"key":"10345_CR30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340\u20131346. https:\/\/doi.org\/10.1093\/annonc\/mdu110","journal-title":"Ann Oncol"},{"key":"10345_CR31","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328\u20131333. https:\/\/doi.org\/10.1093\/annonc\/mdu101","journal-title":"Ann Oncol"},{"key":"10345_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333\u20131339. https:\/\/doi.org\/10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"key":"10345_CR33","doi-asserted-by":"publisher","first-page":"S1599","DOI":"10.1016\/j.annonc.2024.10.565","volume":"35","author":"L Xu","year":"2024","unstructured":"Xu L, Sun Y, Meng F, Liu C, Guan S, Zhong D, Zhang L (2024) 538P Prolonged usage of NEPA for prevention of long-delayed CINV in patients receiving highly emetogenic chemotherapy. Ann Oncol 35:S1599. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.565","journal-title":"Ann Oncol"},{"key":"10345_CR34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1080\/14796694.2025.2479417","volume":"21","author":"YH Park","year":"2025","unstructured":"Park YH, Bianchini G, Cort\u00e9s J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scott\u00e9 F, Schwartzberg L, Navari RM, Aapro M, Rugo HS (2025) Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol 21:1261\u20131272. https:\/\/doi.org\/10.1080\/14796694.2025.2479417","journal-title":"Future Oncol"},{"key":"10345_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40266-023-01056-y","volume":"40","author":"A Blaszcyk","year":"2023","unstructured":"Blaszcyk A, Brandt N, Ashley J, Tuders N, Doles H, Stefanacci RG (2023) Crushed tablet administration for patients with dysphagia and enteral feeding: challenges and considerations. Drugs Aging 40:895\u2013907. https:\/\/doi.org\/10.1007\/s40266-023-01056-y","journal-title":"Drugs Aging"},{"key":"10345_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/1078155220965671","volume":"27","author":"K Behbahany","year":"2021","unstructured":"Behbahany K, Bubalo J (2021) Capsule-related dysphagia and the use of netupitant\/palonosetron (Akynzeo\u2122) capsules \u2013 a report of two cases and a solution. J Oncol Pharm Pract 27:1284\u20131286. https:\/\/doi.org\/10.1177\/1078155220965671","journal-title":"J Oncol Pharm Pract"},{"key":"10345_CR37","unstructured":"European Medicines Agency (2020) Akynzeo 300 mg\/0.5 mg hard capsules [summary of product characteristics]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akynzeo-epar-product-information_en.pdf. Accessed 26 August 2025"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10345-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:03:52Z","timestamp":1771275832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10345-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10345"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10345-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the International Council for Harmonization requirements and the Declaration of Helsinki. The study protocol was approved by the relevant independent ethics committees or institutional review boards. Signed written informed consent was obtained prior to study initiation.\n                      Ethics committee:\n                      Bezeichnung der Ethik-Kommission:Ethikkommission bei der Medizinischen Fakult\u00e4t der.Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen.Pettenkoferstra\u00dfe 8.80336 M\u00fcnchen.GERMANY","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Signed written informed consent was obtained from all study participants prior to study initiation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A; no individual participant\u2019s details are included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Edis Gasanin \u2013 Study funding: Helsinn Healthcare SA. Friedeborg Seitz \u2013 Study funding: Helsinn Healthcare SA. Riccordo Bezzo \u2013 employee of Helsinn Healthcare SA. Tulla Spinelli \u2013 employee of Helsinn Healthcare SA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}